DGAP-News: Marinomed Biotech AG / Key word(s): Patent
Marinomed Biotech AG announces grant of Chinese Patent covering the proprietary Marinosolv technology to generate aqueous solutions from insoluble compounds
Korneuburg, Austria, July 15, 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, is pleased to announce that the Chinese State Intellectual Property Office (SIPO) has granted the patent covering the Marinosolv platform and its solubilizer properties. Specifically, the patent protects Marinosolv as a method for generating aqueous solutions of therapeutically or cosmetically relevant organic compounds that are insoluble or only slightly soluble in water. The Marinosolv platform enables the solubilization of many hardly soluble compounds, which opens new possibilities for precisely treating a multitude of diseases.
"The Marinosolv patent in China is an important international reinforcement of the technology platform and supports our continued efforts in further establishing and advancing Marinosolv-based products. We consider both the Marinosolv-based products and the underlying technology central cornerstones for the company's future development," said Dr. Andreas Grassauer, Chief Executive Officer of Marinomed. "The Chinese market offers huge potential for the treatment of allergic diseases. This patent will help Marinomed to benefit from these opportunities."
"The data from Marinosolv formulated product candidates so far have demonstrated significant efficacy given the comparatively low dosage: this is true for Tacrosolv, a soluble Tacrolimus formulation in development to treat hay fever, as well as for our two corticosteroid formulations against allergic rhinitis, Budesolv and Flutisolv. The increased solubility enables a significantly faster onset of action, better bioavailability and more efficient delivery, making treatment more convenient for patients," said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. "We are confident that formulations based on the Marinosolv technology generally offer much quicker improvement of symptoms for patients suffering from allergic rhinitis, allergic conjunctivitis and a broad range of further conditions where faster relief leads to a significantly improved quality of life."
Marinosolv is a proprietary technology platform enabling aqueous formulations of otherwise poorly soluble compounds. The platform opens application areas for a wide range of therapeutics, unlocking new treatment opportunities. Tacrosolv eye drops have recently successfully completed a Phase II clinical trial in patients with allergic rhinoconjunctivitis. Two corticosteroid formulations against allergic rhinitis are also in advanced development, Budesolv and Flutisolv. Budesolv, a Marinosolv-based Budesonide formulation, has successfully completed a clinical phase III study. For the Fluticasone-based Flutisolv, Marinomed is currently preparing the next step in clinical development. Beyond this late-stage clinical pipeline, Marinosolv also gives rise to a research pipeline, including potential treatment approaches for autoimmune gastritis and other indications.
The solubility and bioavailability of an active pharmaceutical ingredient (API) are central challenges in all pharmaceutical drug development programs and can be a major hurdle for the success of drugs in clinical development. Marinomed developed the Marinosolv platform to specifically address this challenge. Preclinical and clinical studies have shown that Marinosolv-based formulations achieve a higher concentration in the target location or tissue compared to suspensions and other standard formulations, resulting in a better local bioavailability. Besides this, the Marinosolv platform can extend the patent life of approved drugs.
About Marinomed Biotech AG:
15.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.